Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA
Portfolio Pulse from Lara Goldstein
Atai Life Sciences (NASDAQ:ATAI) reported Q2 2023 financial results, with cash and short-term investments of $227.5 million and a net loss attributable to shareholders of $33.1 million. The company's pipeline is advancing 8 programs, six of which are psychedelic-based substances. The Phase 1 trial of oral ibogaine DMX-1002 for Opioid Use Disorder has delivered new clinical results. Other program updates include RL-007, VLS-01, PCN-101, EMP-01, and COMPASS Pathways' COMP360. The company expects its current cash position to fund operations into the first half of 2026.
August 10, 2023 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Atai Life Sciences reported Q2 2023 financial results and updates on its pipeline. The company's current cash position is expected to fund operations into the first half of 2026.
Atai Life Sciences reported its Q2 2023 financial results and provided updates on its pipeline. The company's financial position and progress in its pipeline are key factors that could influence its stock price. However, the impact of this news on the company's stock price in the short term is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
COMPASS Pathways' COMP360, a psilocybin therapy for treatment-resistant depression, anorexia nervosa, and PTSD, is part of Atai Life Sciences' pipeline. Phase 3 program’s long-term topline data is expected by summer 2024.
COMPASS Pathways' COMP360 is part of Atai Life Sciences' pipeline. The progress of this program could have an impact on COMPASS Pathways' stock price. However, the impact of this news on the company's stock price in the short term is uncertain.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50